Clinical Research Directory

Inclusion Criteria: * Recurrent or second upper aerodigestive tract carcinoma in an area previously irradiated at a dose of \>= 50 Gy * Squamous cell carcinoma * No grade III or IV sequels linked to the first radiation therapy (excepted radiation sequels of salivary glands) * Relapse or second carcinoma (clinically invasive and/or lymph node recurrence \>= 3 cm and/or the association of a local and lymph node recurrence * Oral cavity, pharynx, larynx (if rT4), cervical region (if \>3cm) * No distant metastases confirmed by chest CT scan, abdominal ultrasound (or CT scan) in case of abnormal liver function, and bone scintigraphy in case of local symptoms * Surgery in the previously irradiated region allowing a macroscopically adequate resection * Surgery and vascular protection with a myocutaneous or free flap * Interval \> = 6 months between the end of the first radiation treatment and surgery in the previously irradiated area * Wound healing allowing reirradiation within an interval of 8 weeks after surgery in the previouly irradiated area. * No participation in a clinical trial during the 30 days preceding inclusion * Age between 18 et 70 years. * Performance Status 0 or 1 according to WHO criteria. * Hematological function : neutrophils \* 2 x 106/l, platelets : \* 100 x 106/l, hemoglobin : \* 10 g/dl (or 6.2 mmol/l) * Liver function : total bilirubin (normal) ; ASAT (SGOT) and ALAT (SGPT) \* 2.5 \* upper limit of normal (ULN) in each centre ; alkaline phosphatases \* 5 \* ULN. Patients whose ASAT or ALAT levels \> 1.5 \* ULN associated with alkaline phosphatases \* 2.5 \* ULN are not eligible for the trial * Renal function : serum creatinine \* 120 \*mol/l (1.4 mg/dl) ; if creatinine level is \> 120 \*mol/l, creatinine clearance should be \* 60 ml/min. * Written consent of participants Exclusion Criteria: * Superficial recurrence not associated with a lymph node relapse, isolated lymph node recurrence measuring less than 3 cm * Distant metastases * Grade 3 or 4 sequels of first radiation therapy (excepted salivary gland sequels) * Macroscopically inadequate surgery * Delay in wound healing obliging reirradiation to be postponed beyond 8 weeks. * \> Grade 3 Toxicity induced by chemotherapy administered during a previous treatment * Hypersensitivity to Erbitux * Concomitant severe comorbidities (non exhaustive list) * Unstable cardiac comorbidity in spite of treatment. * Neurological or psychiatric history such as dementia, convulsions. * Severe uncontrolled infection * Obstructive bronchopneumopathy which required hospitalisation during the year preceding inclusion. * Factors (psychological, familial, social or geographic) likely to hinder patient compliance with the study protocol and follow-up are considered exclusion criteria. These factors should be discussed with the patient before enrollment in the trial * Women who are pregnant, breast-feeding or of birthgiving age without effective contraception